Cargando…
Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
This study assessed the endocrine pancreatic responses to liraglutide (0.9 mg once a day) during normal living conditions in Japanese patients with type 2 diabetes. The study included 14 hospitalized patients with type 2 diabetes. Meal tests were performed after improvement of glycemic control achie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
the Society for Free Radical Research Japan
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705157/ https://www.ncbi.nlm.nih.gov/pubmed/23874074 http://dx.doi.org/10.3164/jcbn.13-14 |
_version_ | 1782476394409754624 |
---|---|
author | Matsumoto, Shinobu Yamazaki, Masahiro Kadono, Mayuko Iwase, Hiroya Kobayashi, Kanae Okada, Hiroshi Fukui, Michiaki Hasegawa, Goji Nakamura, Naoto |
author_facet | Matsumoto, Shinobu Yamazaki, Masahiro Kadono, Mayuko Iwase, Hiroya Kobayashi, Kanae Okada, Hiroshi Fukui, Michiaki Hasegawa, Goji Nakamura, Naoto |
author_sort | Matsumoto, Shinobu |
collection | PubMed |
description | This study assessed the endocrine pancreatic responses to liraglutide (0.9 mg once a day) during normal living conditions in Japanese patients with type 2 diabetes. The study included 14 hospitalized patients with type 2 diabetes. Meal tests were performed after improvement of glycemic control achieved by two weeks of multiple insulin injection therapy and after approximately two weeks of liraglutide treatment. Continuous glucose monitoring was performed to compare daily variation in glycemic control between multiple insulin injection therapy and liraglutide treatment. Liraglutide reduced plasma glucose levels after the test meals (60–180 min; p<0.05), as a result of significant increases in insulin secretion (0–180 min; p<0.05) and decreases in the incremental ratio of plasma glucagon (15–60 min; p<0.05). Continuous glucose monitoring showed that liraglutide treatment was also associated with a decrease in glucose variability. We also demonstrated that optimal glycemic control seen as a reduction in 24-h mean glucose levels and variability was obtained only with liraglutide monotherapy. In conclusion, liraglutide treatment increases insulin secretion and suppresses glucagon secretion in Japanese patients with type 2 diabetes under normal living conditions. The main therapeutic advantages of liraglutide are its use as monotherapy and its ability to decrease glucose variability. |
format | Online Article Text |
id | pubmed-3705157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | the Society for Free Radical Research Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-37051572013-07-19 Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes Matsumoto, Shinobu Yamazaki, Masahiro Kadono, Mayuko Iwase, Hiroya Kobayashi, Kanae Okada, Hiroshi Fukui, Michiaki Hasegawa, Goji Nakamura, Naoto J Clin Biochem Nutr Original Article This study assessed the endocrine pancreatic responses to liraglutide (0.9 mg once a day) during normal living conditions in Japanese patients with type 2 diabetes. The study included 14 hospitalized patients with type 2 diabetes. Meal tests were performed after improvement of glycemic control achieved by two weeks of multiple insulin injection therapy and after approximately two weeks of liraglutide treatment. Continuous glucose monitoring was performed to compare daily variation in glycemic control between multiple insulin injection therapy and liraglutide treatment. Liraglutide reduced plasma glucose levels after the test meals (60–180 min; p<0.05), as a result of significant increases in insulin secretion (0–180 min; p<0.05) and decreases in the incremental ratio of plasma glucagon (15–60 min; p<0.05). Continuous glucose monitoring showed that liraglutide treatment was also associated with a decrease in glucose variability. We also demonstrated that optimal glycemic control seen as a reduction in 24-h mean glucose levels and variability was obtained only with liraglutide monotherapy. In conclusion, liraglutide treatment increases insulin secretion and suppresses glucagon secretion in Japanese patients with type 2 diabetes under normal living conditions. The main therapeutic advantages of liraglutide are its use as monotherapy and its ability to decrease glucose variability. the Society for Free Radical Research Japan 2013-07 2013-06-01 /pmc/articles/PMC3705157/ /pubmed/23874074 http://dx.doi.org/10.3164/jcbn.13-14 Text en Copyright © 2013 JCBN This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Matsumoto, Shinobu Yamazaki, Masahiro Kadono, Mayuko Iwase, Hiroya Kobayashi, Kanae Okada, Hiroshi Fukui, Michiaki Hasegawa, Goji Nakamura, Naoto Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes |
title | Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes |
title_full | Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes |
title_fullStr | Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes |
title_full_unstemmed | Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes |
title_short | Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes |
title_sort | effects of liraglutide on postprandial insulin and glucagon responses in japanese patients with type 2 diabetes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705157/ https://www.ncbi.nlm.nih.gov/pubmed/23874074 http://dx.doi.org/10.3164/jcbn.13-14 |
work_keys_str_mv | AT matsumotoshinobu effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes AT yamazakimasahiro effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes AT kadonomayuko effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes AT iwasehiroya effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes AT kobayashikanae effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes AT okadahiroshi effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes AT fukuimichiaki effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes AT hasegawagoji effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes AT nakamuranaoto effectsofliraglutideonpostprandialinsulinandglucagonresponsesinjapanesepatientswithtype2diabetes |